Equity in vaccine trials for higher weight people? A rapid review of weight-related inclusion and exclusion criteria for COVID-19 clinical trials
Author | Campbell, Jessica |
Author | Sutherland, Juliet |
Author | Bucknall, Danielle |
Author | O’hara, Lily |
Author | Heywood, Anita |
Author | Hobbs, Matthew |
Author | Ballantyne, Angela |
Author | Gray, Lesley |
Available date | 2022-08-22T07:05:24Z |
Publication Date | 2021-12-01 |
Publication Name | Vaccines |
Identifier | http://dx.doi.org/10.3390/vaccines9121466 |
Citation | Campbell, J.; Sutherland, J.; Bucknall, D.; O’Hara, L.; Heywood, A.; Hobbs, M.; Ballantyne, A.; Gray, L. Equity in Vaccine Trials for Higher Weight People? A Rapid Review of Weight-Related Inclusion and Exclusion Criteria for COVID-19 Clinical Trials. Vaccines 2021, 9, 1466. https://doi.org/10.3390/vaccines9121466 |
Abstract | Higher weight status, defined as body mass index (BMI) ≥ 30 kg/m2, is frequently described as a risk factor for severity and susceptibility to severe acute respiratory syndrome coron-avirus 2 (SARS-CoV-2) disease (known as COVID-19). Therefore, study groups in COVID-19 vaccine trials should be representative of the weight spectrum across the global population. Appropriate subgroup analysis should be conducted to ensure equitable vaccine outcomes for higher weight people. In this study, inclusion and exclusion criteria of registered clinical trial protocols were reviewed to determine the proportion of trials including higher weight people, and the proportion of trials conducting subgroup analyses of efficacy by BMI. Eligibility criteria of 249 trial protocols (phase I, II, III and IV) were analysed; 51 protocols (20.5%) specified inclusion of BMI > 30, 73 (29.3%) specified exclusion of BMI > 30, and 125 (50.2%) did not specify whether BMI was an inclusion or exclusion criterion, or if BMI was included in any ‘health’ screenings or physical examinations during recruitment. Of the 58 protocols for trials in phase III and IV, only 2 (3.4%) indicated an intention to report subgroup analysis of vaccine efficacy by weight status. Higher weight people appear to be significantly under-represented in the majority of vaccine trials. This may result in reduced efficacy and acceptance of COVID-19 vaccines for higher weight people and exacerbation of health inequities within this population group. Explicit inclusion of higher weight people in COVID-19 vaccine trials is required to reduce health inequities. |
Language | en |
Publisher | MDPI |
Subject | BMI Clinical trial COVID-19 Equity Higher weight Inequity Vaccination Vaccine |
Type | Article |
Issue Number | 12 |
Volume Number | 9 |
ESSN | 2076-393X |
Files in this item
This item appears in the following Collection(s)
-
COVID-19 Research [799 items ]
-
Public Health [401 items ]